AstraZeneca and Ionis gene silencer Wainua fails trial after patients also took Pfizer heart drug

At the ESC Congress in Munich, a high‑profile trial of the gene‑silencing therapy Wainua, developed by AstraZeneca and Ionis, was reported to have failed.

The failure was linked to participants concurrently receiving a Pfizer medication for the same heart condition, which may have confounded the results.

The setback raises uncertainty about the future development of the therapy and could delay its potential market entry.